Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) LANCET HAEMATOLOGY Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., Press, O. W., Salles, G., Tilly, H., Chen, A. I., Assouline, S., Cheson, B. D., Dreyling, M., Hagenbeek, A., Zinzani, P., Jones, S., Cheng, J., Lu, D., Penuel, E., Hirata, J., Wenger, M., Chu, Y., Sharman, J. 2019; 6 (5): E254–E265

View details for DOI 10.1016/S2352-3026(19)30026-2

View details for Web of Science ID 000466131400008